This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy. Clinical, imaging, and pathological data from previously treated patients will be collected and analyzed. The model is expected to assist in predicting treatment outcomes and guide personalized therapeutic strategies.
Pathologically confirmed esophageal squamous cell carcinoma (ESCC).
Received at least one cycle of neoadjuvant chemotherapy combined with immunotherapy.
Underwent contrast-enhanced chest CT before initiation of neoadjuvant treatment.
Underwent contrast-enhanced chest CT after completion of neoadjuvant treatment and prior to surgery.
Diagnosis of other malignancies.
Received other anti-tumor therapies before or during neoadjuvant chemo-immunotherapy.
Incomplete clinical data.
Poor-quality CT imaging.